{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-23-000063","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.505061+00:00","generated_at":"2026-06-12T01:01:38.602842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amphastar Q2 2023 revenue $145.7M, GAAP EPS $0.49, adj. EPS $0.65","bullets":["Net revenues $145.7M for Q2 2023, up 18% from $123.5M in Q2 2022.","GAAP net income $26.1M ($0.49 diluted EPS) vs $17.3M ($0.33) YoY.","Adjusted non-GAAP net income $34.8M ($0.65 diluted EPS) vs $20.7M ($0.39) YoY.","Completed BAQSIMI acquisition June 30; glucagon, phytonadione, and newer products drove growth.","Six-month: revenue $285.7M, GAAP net income $52.2M ($0.99 EPS), adj. net income $66.9M ($1.27 EPS)."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-23-000063","json":"https://secwatch.observer/filing/0001297184-23-000063.json","markdown":"https://secwatch.observer/filing/0001297184-23-000063.md","text":"https://secwatch.observer/filing/0001297184-23-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000063/0001297184-23-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000063/amph-20230808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:01:38.602842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}